- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02307604
SPECTAbrain: Screening Patients With Brain Tumors for Efficient Clinical Trial Access (SPECTAbrain)
June 20, 2019 updated by: European Organisation for Research and Treatment of Cancer - EORTC
Screening Platform of EORTC for Clinical Trials Access in Brain Tumors
The SPECTAbrain protocol describes a structure for screening patients with brain tumors to efficiently allocate eligible patients in relevant therapeutic biomarker-driven clinical trials. Efficiency is promoted through the creation of a clinical database of brain tumor patients and the respective human biological material biobank for molecular characterization. The main objectives are to:
- Allocate patients to clinical trials according to the clinical characteristics and molecular profile of their tumor;
- Identify or validate new molecularly defined subgroups of tumors;
- Investigate the prevalence of novel biomarkers to plan future clinical trials;
- Enable exploratory/future research;
- Facilitate establishment of quality-assured and validated tests for Central Nervous System (CNS) tumor biomarkers;
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Observational
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Lille, France, FR 59037
- CHRU de Lille
-
Paris, France, FR 75651
- Assistance Publique - Hopitaux de Paris - La Pitie Salpetriere
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with pathologically confirmed brain cancer at any stage.
Description
Inclusion Criteria:
- Pathologically confirmed newly diagnosed primary CNS tumors, with a focus on diffuse gliomas of grades II, III and IV, meningiomas from patients who are candidates for pharmacotherapy, and rare CNS tumors;
- Availability of adequate Human Biological Material (HBM): FFPE tissue sample from the primary and/or recurrent tumor and/or metastasis, obtained at the time of surgery or biopsy; minimal amount requested is detailed in the HBM guidelines. Inclusion of samples taken at any recurrence diagnosed during follow-up is strongly encouraged but optional;
- At least three months life expectancy;
- Written informed consent according to ICH/GCP and national/local regulations;
- Absence of exclusion criteria, such as active hepatitis B/C or HIV, second malignancies, severe organ dysfunction, or other comorbidities that will prevent inclusion into clinical trials.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Brain cancer
Patients with diagnosis of brain cancer at any stage
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of patients with brain malignancy
Time Frame: 5 years
|
5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Michael Weller, MD, UniversitaetsSpital Zurich - Department of Neurology, Zurich, Switzerland
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2016
Primary Completion (Anticipated)
January 1, 2019
Study Completion (Anticipated)
January 1, 2019
Study Registration Dates
First Submitted
December 2, 2014
First Submitted That Met QC Criteria
December 2, 2014
First Posted (Estimate)
December 4, 2014
Study Record Updates
Last Update Posted (Actual)
June 24, 2019
Last Update Submitted That Met QC Criteria
June 20, 2019
Last Verified
June 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EORTC-1313
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Neoplasms
-
National Cancer Institute (NCI)CompletedBrain Cancer | Brain Neoplasm | Brain Tumor, PrimaryUnited States
-
Constantinos HadjipanayisNational Cancer Institute (NCI); NX PharmaGenWithdrawnGlioblastoma | Brain Cancer | Brain Tumors | Brain Tumor, Recurrent | Benign Neoplasms, Brain | Brain Neoplasms, Benign | Brain Neoplasms, Malignant | Brain Tumor, Primary | Intracranial Neoplasms | Neoplasms, Brain | Neoplasms, Intracranial | Primary Brain Neoplasms | Primary Malignant Brain Neoplasms | Primary Malignant... and other conditionsUnited States
-
Vanderbilt University Medical CenterUniversity of Alabama at Birmingham; Emory University; H. Lee Moffitt Cancer... and other collaboratorsTerminatedBrain Neoplasms, Benign | Brain Neoplasms, Malignant | Brain Neoplasm, PrimaryUnited States
-
BioNumerik Pharmaceuticals, Inc.Crown BioscienceCompletedBrain Neoplasms | Brain Tumors | Malignant Neoplasms, BrainUnited States
-
University of Erlangen-Nürnberg Medical SchoolNot yet recruitingBrain Tumor, Primary | Brain Tumor - MetastaticGermany
-
National Cancer Institute (NCI)TerminatedCentral Nervous System Neoplasms | Brain Cancer | Neoplasms, Brain | Primary Brain Neoplasms | Cancer of the BrainUnited States
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedBrain Stem Neoplasms, Primary | Neoplasms, Brain StemUnited States
-
Lawson Health Research InstituteCompletedBrain Tumor | Brain Neoplasm | Tumor, Brain | Neoplasm, Supratentorial | Tumor, SupratentorialCanada
-
University of NebraskaRecruitingPrimary Brain Tumor | Metastatic Brain TumorUnited States
-
Mayo ClinicRecruitingBrain Tumor | Brain Tumor Adult | Brain LesionUnited States
Clinical Trials on Tumour markers testing
-
European Organisation for Research and Treatment...ETOP IBCSG Partners FoundationCompletedSPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access (SPECTAlung)Any Stage of Lung Cancer (Any Histotype) | Any Stage of Malignant Pleural Mesothelioma | Any Stage of Any Thymic MalignancySpain, Belgium, Ireland, Slovenia, France, United Kingdom, Poland, Italy, Switzerland
-
European Organisation for Research and Treatment...CompletedColorectal Cancer | Advanced Colorectal CancerBelgium, Switzerland, Poland, Spain, France, Italy, Germany, Cyprus, Greece, Portugal, Sweden
-
University Health Network, TorontoCanadian Cancer Trials Group; Princess Margaret Hospital, CanadaCompleted
-
Royal Marsden NHS Foundation TrustImperial College London; St. George's NHS Foundation TrustUnknown
-
Walter and Eliza Hall Institute of Medical ResearchJohns Hopkins UniversityActive, not recruitingOvarian CancerAustralia, United States
-
Shi YunNot yet recruitingBone Diseases, Metabolic | Bone Mineral Density | Premature Ovarian InsufficiencyChina
-
Xinhua Hospital, Shanghai Jiao Tong University...CNOG-MC001 Collaborative GroupCompletedPediatric Brain Tumor | Malignant Brain Tumor | Tumors, Central Nervous System | Benign Brain TumorChina
-
University Hospital OstravaCompleted
-
Royal North Shore HospitalUniversity of SydneyRecruitingLung Cancer | Markerless Image Guidance | Intrafraction Kolovoltage X-ray ImagingAustralia
-
Wroclaw Medical UniversityTerminated